After announcing last week a co-marketing pact with PerkinElmer in the cell analysis field, Invitrogen CEO Greg Lucier told attendees of the UBS Global Life Sciences conference in New York this week that they should expect the company to make further moves to build its presence in that market.

For PerkinElmer, the deal could help it gain better overall name recognition in cell-based screening, which could help its LumiLux platform gain market penetration more rapidly.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.